Ipledgeprogram.com — Website Analysis
Comprehensive traffic, valuation, and technical report for ipledgeprogram.com
ipledgeprogram.com has a global rank of #214,807 with an estimated 36 daily visitors. Based on current traffic levels, the domain is valued at approximately $32,587.
The site runs on a .com (commercial) domain with servers located in United States, primary IP address 208.67.124.30, an active HTTPS configuration. Its homepage is titled “iPLEDGE REMS”.
| SSL Certificate | Secure |
| Security Score | 0% |
| Strict-Transport-Security | ✗ |
| Content-Security-Policy | ✗ |
| X-Content-Type-Options | ✗ |
| X-Frame-Options | ✗ |
| X-XSS-Protection | ✗ |
Based on our analysis, ipledgeprogram.com implements HTTPS encryption and scores 0% on security headers. There is room for improvement in security configuration.
| Purchase/Sale Value | $32,587 |
| Daily Revenue | $24 |
| Monthly Revenue | $679 |
| Yearly Revenue | $8,147 |
| Daily Visitors | 36 |
All values are estimates based on publicly available traffic data.
These are the websites closest to ipledgeprogram.com in global traffic ranking.
| Website | ipledgeprogram.com |
| Domain Age | 2005-05-31 11:11:54 |
| TLD | .com |
| Hosting Location | United States |
| Primary IP | 208.67.124.30 |
| Host | Type | IP | Nameserver |
|---|---|---|---|
| ipledgeprogram.com | A | 208.67.124.30 | ns2.ubc.com. |
| ipledgeprogram.com | A | 40.142.58.58 | ns1.ubc.com. |
Cache-Control
Content-Length
Content-Security-Policy
Content-Type
Date
Expect-CT
Expires
Pragma
Referrer-Policy
Set-Cookie
Strict-Transport-Security
X-Content-Type-Options
X-Frame-Options
X-XSS-Protection
| Domain Name | IPLEDGEPROGRAM.COM, ipledgeprogram.com |
| Registrar | GoDaddy.com, LLC |
| Whois Server | whois.godaddy.com |
| Referral Url | None |
| Updated Date | 2023-04-24 21:26:10, 2023-04-24 16:26:08 |
| Creation Date | 2005-05-31 11:11:54, 2005-05-31 06:11:54 |
| Expiration Date | 2026-05-31 11:11:54, 2026-05-31 06:11:54 |
| Name Servers | NS1.UBC.COM, NS2.UBC.COM |
| Status | clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited, clientRenewProhibited https://icann.org/epp#clientRenewProhibited, clientTransferProhibited https://icann.org/epp#clientTransferProhibited, clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited |
| Emails | [email protected] |
| Dnssec | unsigned |
| Name | Registration Private |
| Org | Domains By Proxy, LLC |
| Address | DomainsByProxy.com, 2155 E Warner Rd |
| City | Tempe |
| State | Arizona |
| Registrant Postal Code | 85284 |
| Country | US |
How much is ipledgeprogram.com worth?
ipledgeprogram.com has an estimated value of $32,587 based on its traffic volume, global ranking, and projected advertising revenue.
How much traffic does ipledgeprogram.com get?
ipledgeprogram.com receives approximately 36 unique visitors per day. Its global traffic rank is #214,807.
Is ipledgeprogram.com safe to visit?
ipledgeprogram.com uses HTTPS encryption and has an active SSL certificate, which is a positive indicator of security. Always exercise caution when entering personal information on any website.
Where is ipledgeprogram.com hosted?
The servers for ipledgeprogram.com are located in United States.
Who owns ipledgeprogram.com?
Ownership details for ipledgeprogram.com can be found in the WHOIS section below. Many domain owners use privacy protection services to keep their registration details private.
How does ipledgeprogram.com rank compared to other .com websites?
With a global rank of #214,807, ipledgeprogram.com is a recognized .com domain.
| Domain | ipledgeprogram.com |
| TLD | .com |
| SSL | Secure |
| Server Location | United States |
| Global Rank | #214,807 |
| Registrar | GoDaddy.com, LLC |
| Domain Age | 2005-05-31 11:11:54 |
| Title | iPLEDGE REMS |
| Description | The iPLEDGE PROGRAM REMS (Risk Evaluation and Mitigation Strategy) The iPLEDGE PROGRAM REMS is a safety program to manage the risk of isotretinoin’s teratogenicity and to minimize fetal exposure. The REMS is required by the U.S. Food and Drug Administration (FDA) to ensure the benefits of isotretinoin outweigh its risks. |